Fonar Corporation (FONR)vsIDEXX Laboratories Inc (IDXX)
FONR
Fonar Corporation
$19.09
0.00%
HEALTHCARE · Cap: $120.20M
IDXX
IDEXX Laboratories Inc
$504.70
-0.36%
HEALTHCARE · Cap: $40.98B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 4222% more annual revenue ($4.55B vs $105.34M). IDXX leads profitability with a 25.0% profit margin vs 6.3%. FONR trades at a lower P/E of 19.1x. IDXX earns a higher WallStSmart Score of 63/100 (C+).
FONR
Hold38
out of 100
Grade: F
IDXX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.7%
Fair Value
$14.66
Current Price
$19.09
$4.43 premium
Margin of Safety
-48.7%
Fair Value
$436.26
Current Price
$504.70
$68.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Every $100 of equity generates 71 in profit
Strong operational efficiency at 35.0%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Areas to Watch
Smaller company, higher risk/reward
ROE of 5.5% — below average capital efficiency
6.3% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 24.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : FONR
The strongest argument for FONR centers on Price/Book, Altman Z-Score, Debt/Equity.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.
Bear Case : FONR
The primary concerns for FONR are Market Cap, Return on Equity, Profit Margin.
Bear Case : IDXX
The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.
Key Dynamics to Monitor
FONR profiles as a value stock while IDXX is a mature play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.54 — expect wider price swings.
IDXX is growing revenue faster at 9.7% — sustainability is the question.
IDXX generates stronger free cash flow (323M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 38/100), backed by strong 25.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fonar Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
FONAR Corporation is engaged in the research, development, production, and marketing of Magnetic Resonance Imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company is headquartered in Melville, New York.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?